Influenza vaccines are prepared using virus strains in line with the WHO recommendations
- some inactivated influenza vaccines are trivalent, containing two subtypes of influenza A and one B virus; however, quadrivalent vaccines that contain an additional B virus have now become routinely available (1)
All but one of the influenza vaccines available in the UK are inactivated and cannot cause clinical influenza in those that are vaccinated
- the live attenuated influenza vaccine (LAIV) 'Fluenz Tetra' contains live
viruses that have been attenuated (weakened) and adapted to cold so that they
can only replicate at the lower temperatures found in the nasal passage
- these live viruses cannot replicate efficiently elsewhere in the body
but may cause mild coryzal symptoms
- these live viruses cannot replicate efficiently elsewhere in the body but may cause mild coryzal symptoms
- the inactivated vaccines are administered by intramuscular injection
- LAIV is administered by nasal spray
- most of the vaccines are prepared from viruses grown in embryonated hens'
- if a new influenza A subtype were to emerge with epidemic or pandemic potential
(as occurred in 2009 with influenza A(H1N1)v), it is unlikely that the influenza
vaccine will be well matched to the emerging strain
- as occurred during the second wave of the 2009 pandemic, a monovalent
vaccine against that strain may be developed and implemented
- as occurred during the second wave of the 2009 pandemic, a monovalent vaccine against that strain may be developed and implemented
- after immunisation, protective immune responses may be achieved within 14 days
Vaccination is best undertaken between September and early November and immunity
can be expected to last for at least the duration of winter (1).
A systematic review concerning the efficacy of influenza vaccination concluded that (2):
- influenza vaccines are effective in reducing serologically confirmed cases of influenza
- influenza vaccines are not as effective in reducing cases of clinical influenza and number of working days lost
- universal immunisation of healthy adults is not supported by the results of this review
A systematic review concerning the efficacy of influenza vaccination in patients with chronic obstructive pulmonary disease (COPD) concluded that (3):
- inactivated vaccine reduces exacerbations in COPD patients
- there was a reduction in exacerbations occurring three or more weeks after vaccination
- there was a mild increase in transient local adverse effects with vaccination, but no evidence of an increase in early exacerbations
With specific reference to use of the influenza vaccine in healthy children (4):
- in healthy children > 2 years of age, both live attenuated vaccines and inactivated vaccines prevent influenza and influenza-like illness
Check uptodate details in the The Green Book before prescribing/administering an influenza vaccination.
Check the Summary of Product Characteristics (SPC) of the influenza vaccination before prescribing/administering an influenza vaccine.
- the live attenuated influenza vaccine (Fluenz) should not be given to children or adolescents who are clinically severely immunodeficient due to conditions or immunosuppressive therapy (1)
- (1) Immunisation Against Infectious Disease - "The Green Book". Chapter 19. Influenza (April 2019)
- (2) Demicheli V et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2004;(3):CD001269.
- (3) Poole PJ et al. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;(1):CD002733
- (4) Smith S et al. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2006;(1):CD004879.
Last edited 04/2019